Journal of Oncology Pharmacy Practice (JOPP) is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer AD describing innovative pharmacy distributive and clinical models.
Publishing comprehensive and critical reviews of clinical drug use in cancer patient care, research related to oncology pharmacy practice, institutional policies on medication use, with outcome indicators, reports of innovative services, policies, and outcome measure tools, case reports describing interesting adverse reactions and therapeutic responses, this practical journal also includes information on new products, new therapies and patient management.
Please note: JOPP does not include any preclinical studies and authors should consider submitting these types of papers to the appropriate Sage journal.
As the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP), the Journal of Oncology Pharmacy Practice contains regular updates on ISOPP activities, as well as practical issues relating to oncology pharmacy and worker safety.
This journal is a member of the Committee on Publication Ethics (COPE).
Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer and is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP).
As the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP), the Journal of Oncology Pharmacy Practice contains regular updates on ISOPP activities, as well as practical issues relating to oncology pharmacy and worker safety.
JOPP articles include:
Comprehensive and critical reviews of drug use in cancer patient care
Information on new products, new therapies and patient management
Research related to oncology pharmacy practice
Institutional policies on medication use
Reports of innovative services, policies, and outcome measure tools
Brief comments on articles published in the journal or other information of interest
Opinions about controversial therapeutic areas and comments about practice-related issues
Please note: JOPP does not include:
Preclinical studies except medication stability/compatibility
Research on efficacy of cancer treatments
Papers solely reporting radiation or surgery for cancer management
Authors should contact the editor (email@example.com) if they have a question about whether a proposed paper falls within the scope of the Journal of Oncology Pharmacy Practice before submitting their manuscript.
|Barry R Goldspiel||Bethesda, MD, USA|
|Alexandre Chan||University of California, Irvine, CA, USA|
|Graham Sewell (Emeritis)||Plymouth University, UK|
|Marliese Alexander||Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Australia|
|M. Brooke Bernhardt||Baylor College of Medicine, Houston, Texas, USA|
|John E Brown||Kingston University, UK|
|Carole Chambers||Alberta Health Services Pharmacy, Canada|
|Thomas Connor||Cincinnati, USA|
|Sylvie Crauste-Manciet||University of Paris V - Rene Descartes, France|
|Melanie Dalby||King’s College Hospital NHS Foundation Trust, London UK|
|Mario De Lemos||BC Cancer Agency, Vancouver, Canada|
|George Dranitsaris||Ontario Cancer Institute (OCI), Princess Margaret Hospital, Ontario, Canada|
|Salim Hadad||Rambam Health Care Campus, Haifa, Israel|
|Lisa Holle||University of Connecticut School of Pharmacy, Storrs, CT, USA|
|Sabine Kaestner||University Hospital Malmo, Sweden|
|Esin Aysel Kandemir||Carl von Ossietzky University of Oldenburg, Wiefelstede Germany|
|Polly E Kintzel||Spectrum Health Hospitals, USA|
|Shereen Nabhani||Kingston University, UK|
|Lynne Nakashima||BC Cancer Agency, Vancouver Cancer Centre, Canada|
|Manit Saeteaw||Ubon Ratchathani University, Ubon Ratchathani, Thailand|
|Rowena Schwartz||University of Cincinnati, USA|
|Judith Smith||The University of Texas Health Science Center at Houston, USA|
|Lindsay Stansfield||Denver Health, Denver, CO, USA|
|Nicola Stoner||Cancer Research UK, Oxford, UK|
|Gunter Wiedemann||Oberschwabenklinik, Ravensburg, Germany|
|Keary Zhou||The Chinese University of Hong Kong, Shatin, N.T., Hong Kong|
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the Journal’s submission site http://mc.manuscriptcentral.com/jopp to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Journal of Oncology Pharmacy Practice will be reviewed.
There are no fees payable to submit or publish in this journal.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
- What do we publish?
1.1 Aims & Scope
1.2 Article types
1.3 Writing your paper
- Editorial policies
2.1 Peer review policy
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical trials
2.8 Reporting guidelines
- Publishing policies
3.1 Publication ethics
3.2 Contributor's publishing agreement
3.3 Open access and author archiving
- Preparing your manuscript
4.2 Artwork, figures and other graphics
4.3 Supplementary material
4.4 Reference style
4.5 English language editing services
- Submitting your manuscript
5.2 Information required for completing your submission
- On acceptance and publication
6.1 Sage Production
6.2 Online First publication
6.3 Access to your published article
6.4 Promoting your article
Before submitting your manuscript to Journal of Oncology Pharmacy Practice, please ensure you have read the Aims & Scope.
The Journal of Oncology Pharmacy Practice (JOPP) is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer and is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP).
JOPP publishes cancer drug therapy and cancer disease management review articles, research papers, pertinent case reports, editorials, and consensus guidelines that drive clinical practice.
As the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP), JOPP contains articles about practical issues relating to oncology pharmacy including papers about safe handling of cytotoxic agents.
Manuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another publication. However, the journal will consider manuscripts previously presented as limited posters and abstracts during conferences or in supplements.
The journal publishes review articles, original research papers, practice guidelines, practice issues, case reports, letters to the editor, and editorials/commentaries.
Submissions of any article type do not have a strict restriction on word count, tables/figures or references. Submitting authors are encouraged to use what is necessary and appropriate for their manuscript, but note that the peer review process may suggest or request a reduction in any of these aspects.
Review Articles. Comprehensive and critical reviews of drug use in cancer patient care. For medication review articles please include introduction, pharmacology, pharmacokinetics/ pharmacodynamics, therapeutic use, clinical use controversies, product description (cost, special preparation and/or administrative considerations), and perspectives on use (summary paragraph including how this drug fits into current practice). For disease and supportive care management reviews include introduction, epidemiology, etiology, pathophysiology, patient presentation, common staging systems used (for malignancy treatment reviews), treatment (include surgery, radiation, but focus on drug therapy aspects), and summary. It is highly desirable to include a flow-diagram treatment algorithm to summarize disease management.
Original Research Articles. Articles should include a clear statement of purpose; a brief historical review; and a description of the methods, procedures, subjects used, statistical analysis, results, discussion, and conclusions (with clinical implications). For research involving human subjects, a statement must be included to assure that the principles set forth in the the Declaration of Helsinki 1975, revised Hong Kong 1989, were followed or that approval from a local or regional committee on human investigation was obtained. A statement must also be included attesting that informed consent was obtained from each subject or the subject's guardian.
Practice Guidelines. Institutional policies on medication use with outcome indicators.
Practice Issues. Reports of innovative services, policies, or outcome measure tools.
Case Reports/Series. The Journal of Oncology Pharmacy Practice (JOPP) preferentially encourages submission of full-length Review, Original Research, and Practice Issue articles and will not routinely accept Case Reports and/or Case Series. These submissions may be rejected by the Editor-in-Chief without review unless they demonstrate clinical relevance and educational value.
Letters to the Editor. Brief comments on articles published in the Journal or other information of interest to our readers.
Editorials/ Commentaries. Expression of opinions about controversial therapeutic areas or comments about practice-related issues are encouraged.
1.2.1 Abstract guidelines
Please ensure you include the following criteria in your abstract:
Research Article. Introduction (description of rationale for study), Methods (brief description of methods or study design), Results (summary of significant results), and Conclusions (succinct statement of data interpretation).
Review Article. Objective (purpose of article), Data Sources (search criteria), Data Summary, and Conclusions (succinct statement of data interpretation).
Practice Issues Article. Objective (purpose of article), Data Sources (search criteria), Data Summary, and Conclusions (succinct statement about how article will affect practice)
Case Report. Introduction, Case Report, Management & Outcome, Discussion
The Sage Author Gateway has some general advice and on how to get published, plus links to further resources. Sage Author Services also offers authors a variety of ways to improve and enhance their article including English language editing, plagiarism detection, and video abstract and infographic preparation.
1.3.1 Make your article discoverable
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.
The journal's policy is to obtain at least two independent reviews of each article. It operates a double-anonymize reviewing policy in which the reviewer’s name is always concealed from the submitting author; authors may choose to reveal their name but the journal otherwise leaves the article anonymous. Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations.
All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.
If you are asked to provide the names of a peer who could be called upon to review your manuscript, please note that reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
Please note that the journal’s editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
For multi-authored papers a contributor statement outlining what each party contributed to the authorship of the paper should be included in the title page of your submission. Authors should be identified by their initials. An example is shown below.
BF and NP researched literature and conceived the study. MS was involved in protocol development, gaining ethical approval, patient recruitment and data analysis. BF wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.
Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
2.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
- Disclose this type of editorial assistance – including the individual’s name, company and level of input
- Identify any entities that paid for this assistance
- Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
2.3.2 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance”).
It is not necessary to disclose use of language polishing services.
Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.
Journal of Oncology Pharmacy Practice requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Journal of Oncology Pharmacy Practice to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.
Journal of Oncology Pharmacy Practice conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
Sage acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
Journal of Oncology Pharmacy Practice requests all authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at firstname.lastname@example.org
Sage is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the Sage Author Gateway.
Journal of Oncology Pharmacy Practice and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
3.1.2 Prior publication
If material has been previously published it is not generally acceptable for publication in a Sage journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the Sage Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication, Sage requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Sage’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants Sage the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than Sage. In this case copyright in the work will be assigned from the author to the society. For more information please visit the Sage Author Gateway.
Journal of Oncology Pharmacy Practice offers optional open access publishing via the Sage Choice programme. For more information on Open Access publishing options at Sage please visit Sage Open Access. For information on funding body compliance, and depositing your article in repositories, please visit Sage’s Author Archiving and Re-Use Guidelines and Publishing Policies.
Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. LaTeX files are also accepted. The text should be double-spaced throughout and with a minimum of 3cm for left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit Sage’s Manuscript Submission Guidelines.
Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the costs from Sage after receipt of your accepted article.
Images should be supplied as bitmap based files (i.e. with .tiff or .jpeg extension) with a resolution of at least 300 dpi (dots per inch). Line art should be supplied as vector-based, separate .eps files (not as .tiff files, and not only inserted in the Word or pdf file), with a resolution of 600 dpi. Images should be clear, legible, in focus, free of pixilation and not too light or dark.
If, together with your accepted article, you submit usable colour figures, these figures will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the possible costs from Sage after receipt of your accepted article.
In text: tables and figures are either inserted as part of a sentence, for example table 1 or in parentheses for example (figure 1). Each table should carry a descriptive heading. Each figure should be submitted electronically.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. Please contact the Editor (email@example.com) in the first instance. For more information please refer to our guidelines on submitting supplementary files.
Journal of Oncology Pharmacy Practice adheres to the Sage Vancouver reference style. View the Sage Vancouver guidelines to ensure your manuscript conforms to this reference style.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using Sage Language Services. Visit Sage Language Services on our Journal Author Gateway for further information.
Journal of Oncology Pharmacy Practice is hosted on Sage Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/jopp to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
If you would like to discuss your paper prior to submission contact the Editor:
As part of our commitment to ensuring an ethical, transparent and fair peer review process Sage is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the Sage Author Gateway.
Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.
Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the Sage Journals help page for more details, including how to cite Online First articles.
Sage provides authors with online access to their final article.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The Sage Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.